These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22109829)

  • 41. C-kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia.
    Auewarakul CU; Lauhakirti D; Promsuwicha O; Munkhetvit C
    Ann Hematol; 2006 Feb; 85(2):108-12. PubMed ID: 16320053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia.
    De J; Zanjani R; Hibbard M; Davis BH
    Am J Clin Pathol; 2007 Oct; 128(4):550-7. PubMed ID: 17875504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
    Beghini A; Bellini M; Magnani I; Colapietro P; Cairoli R; Morra E; Larizza L
    Exp Hematol; 2005 Jun; 33(6):682-8. PubMed ID: 15911092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia.
    Beghini A; Magnani I; Ripamonti CB; Larizza L
    Hematol J; 2002; 3(3):157-63. PubMed ID: 12111653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nobiletin Down-Regulates c-KIT Gene Expression and Exerts Antileukemic Effects on Human Acute Myeloid Leukemia Cells.
    Chen PY; Chen YT; Gao WY; Wu MJ; Yen JH
    J Agric Food Chem; 2018 Dec; 66(51):13423-13434. PubMed ID: 30507186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
    Pippa R; Dominguez A; Christensen DJ; Moreno-Miralles I; Blanco-Prieto MJ; Vitek MP; Odero MD
    Leukemia; 2014 Sep; 28(9):1915-8. PubMed ID: 24781014
    [No Abstract]   [Full Text] [Related]  

  • 50. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
    Katagiri S; Chi S; Minami Y; Fukushima K; Shibayama H; Hosono N; Yamauchi T; Morishita T; Kondo T; Yanada M; Yamamoto K; Kuroda J; Usuki K; Akahane D; Gotoh A
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.
    Walter G; Ruediger R
    Cell Cycle; 2012 Feb; 11(3):451-9. PubMed ID: 22262169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.
    Arriazu E; Vicente C; Pippa R; Peris I; Martínez-Balsalobre E; García-Ramírez P; Marcotegui N; Igea A; Alignani D; Rifón J; Mateos MC; Cayuela ML; Nebreda AR; Odero MD
    Blood Cancer J; 2020 Jan; 10(1):3. PubMed ID: 31913266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia.
    Xing CY; Hu XQ; Xie FY; Yu ZJ; Li HY; Bin-Zhou ; Wu JB; Tang LY; Gao SM
    FEBS Lett; 2015 Jul; 589(15):1981-7. PubMed ID: 25979172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
    Ruvolo PP; Qui YH; Coombes KR; Zhang N; Ruvolo VR; Borthakur G; Konopleva M; Andreeff M; Kornblau SM
    Leukemia; 2011 Nov; 25(11):1711-7. PubMed ID: 21660042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma.
    Kubota D; Yoshida A; Kawai A; Kondo T
    J Proteome Res; 2014 May; 13(5):2250-61. PubMed ID: 24621013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
    Heo SK; Noh EK; Kim JY; Jeong YK; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Sci Rep; 2017 Nov; 7(1):15278. PubMed ID: 29127384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells.
    Heo SK; Noh EK; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Eur J Pharmacol; 2017 Jun; 804():52-56. PubMed ID: 28322836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.
    Arriazu E; Pippa R; Odero MD
    Front Oncol; 2016; 6():78. PubMed ID: 27092295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis.
    Becker H; Pfeifer D; Afonso JD; Nimer SD; Veelken H; Schwabe M; Lübbert M
    Leukemia; 2008 Sep; 22(9):1792-4. PubMed ID: 18385756
    [No Abstract]   [Full Text] [Related]  

  • 60. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.
    Goswami S; Mani R; Nunes J; Chiang CL; Zapolnik K; Hu E; Frissora F; Mo X; Walker LA; Yan P; Bundschuh R; Beaver L; Devine R; Tsai YT; Ventura A; Xie Z; Chen M; Lapalombella R; Walker A; Mims A; Larkin K; Grieselhuber N; Bennett C; Phelps M; Hertlein E; Behbehani G; Vasu S; Byrd JC; Muthusamy N
    Blood; 2022 Mar; 139(9):1340-1358. PubMed ID: 34788382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.